About the Company
Ramon Martin Chavez (born c. 1964) is an American investment banker and entrepreneur. He is vice chairman and partner of Sixth Street Partners. Previously, he served in a variety of senior roles at Goldman Sachs, including chief information officer (2014–2017), chief financial officer, and global co-head of the firm's Securities Division. Marty was also a partner and member of Goldman's management committee. He was the chief technology officer and co-founder of Quorum Software Systems and CEO and co-founder of Kiodex. He is chairman of the board of computational pharmaceutical company Recursion, Board Observer of biotech company Earli and longevity biopharma company Cambrian Biopharma, and board member of Alphabet Inc. Chavez was appointed president of Harvard University's board of overseers for the 2020–21 academic year.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RXRX News
Recursion Pharmaceuticals Inc (RXRX) Shares Rise Despite Market Challenges
Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has soared by 3.40 in relation to previous closing price of 7.35. Nevertheless, the company has seen a loss of -2.44% in its stock price over ...
Recursion Pharmaceuticals Inc Class A
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals
Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...
Recursion Pharmaceuticals gets grant for pharmaceutical compounds for treating diseases
Discover the groundbreaking patent granted to Recursion Pharmaceuticals Inc for compounds Formula (I) and (II) to treat diseases. Learn about the innovative pharmaceutical compositions and treatment ...
Recursion Pharmaceuticals, Inc. (RXRX)
Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.
Recursion Pharmaceuticals Stock Is Sliding Wednesday: What's Going On?
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower Wednesday after the company reported mixed ...
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
Recursion Pharmaceuticals' market cap currently stands ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner ...
Recursion Pharmaceuticals (NASDAQ: RXRX)
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 11,447 Shares
On April 2, 2024, Blake Borgeson, Director of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 11,447 shares of the company. The transaction was filed with the SEC and can be found through this ...
Recursion Pharmaceuticals Stock (NASDAQ:RXRX), Quotes and News Summary
Inc. (NASDAQ:COIN), Palantir Technologies Inc. (NYSE:PLTR), and Nvidia Corp. Nvidia's AI Revolution Is Transforming Healthcare with Johnson & Johnson and GE Healthcare Partnerships Nvidia ...
Recursion Pharmaceuticals Inc Class A
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...